The correlation of somatic mutations with the clinical outcome of melanoma patients treated with carboplatin/paclitaxel either with or without sorafenib was reported by Melissa et al. The patients harboring BRAF mutation and wild type seemed to have longer survival than those harboring NRAS mutation (15.6 versus 5.6 months) in a chemotherapy arm [16]. Here, BRAF is linked to melanoma.